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http://dx.doi.org/10.1016/j.ccell.2015.07.014SUMMARYCytokines play a pivotal role in regulating tumor immunogenicity and antitumor immunity. IL-36g is impor-
tant for the IL-23/IL-17-dominated inflammation and anti-BCG Th1 immune responses. However, the
impact of IL-36g on tumor immunity is unknown. Here we found that IL-36g stimulated CD8+ T cells, NK
cells, and gd T cells synergistically with TCR signaling and/or IL-12. Importantly, IL-36g exerted profound
antitumor effects in vivo and transformed the tumor microenvironment in favor of tumor eradication.
Furthermore, IL-36g strongly increased the efficacy of tumor vaccination. Moreover, IL-36g expression
inversely correlated with the progression of human melanoma and lung cancer. Our study establishes a
role of IL-36g in promoting antitumor immune responses and suggests its potential clinical translation
into cancer immunotherapy.Significance
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INTRODUCTION
Many tumors induce adaptive immune responses, and the
higher number of tumor-infiltrating type 1 lymphocytes, defined
as interferon g (IFN-g)-producing lymphocytes, correlates with
a better prognosis for cancer patients (Chen et al., 2013; Galon
et al., 2006; Lu et al., 2011; Page`s et al., 2005; Willimsky et al.,
2008). The expression of increased levels of tumor-specific anti-
gens (TSAs) and tumor-associated antigens (TAAs) makes
tumors immunogenic (Blankenstein et al., 2012). However, tu-
mor-specific cellular immune responses induced either sponta-
neously or by tumor vaccination are largely not destructive for
cancer tissues, a sharp contrast to autoimmune responses,
which lead to the obliteration of normal tissues (Blankenstein
et al., 2012). The lack of stimulatory molecules, such as certain
cytokines, and co-stimulatory molecules as well as predominant
immunosuppressive mechanisms in the tumor tissues keeps tu-
mor-specific immune responses in check. Therefore, the identi-
fication of cytokines that have potent antitumor effects should
greatly improve cancer immunotherapy.
Interleukin 36a (IL-36a), IL-36b, and IL-36g, also known as IL-
1F6, IL-1F8, and IL-1F9, respectively, are members of the IL-1
family of cytokines (Gresnigt and van de Veerdonk, 2013). These
cytokines share the same receptor complex, composed of the IL-
36 receptor (IL-36R, also known as IL-1Rrp2 or IL-1RL2) and
IL-1RAcP. The agonistic function of IL-36 is inhibited by the IL-
36 receptor antagonist IL-36RN (also known as IL-1F5) (Gresnigt
and van de Veerdonk, 2013). IL-36g can be induced in keratino-
cytes, bronchial epithelia, brain tissues, and macrophages and
is believed to be an ‘‘alarmin’’ in damaged tissue (Gresnigt and
van de Veerdonk, 2013; Lian et al., 2012). IL-36g exerts its func-
tions directly onmultiple cell types, including tissue stromal cells,
dendritic cells (DCs) and T cells (Foster et al., 2014; Mutamba
et al., 2012; Vigne et al., 2011, 2012). Ample evidence supports
a crucial role of IL-36 cytokines in promoting autoimmunity. For
example, many reports show that IL-36 cytokines are highly
induced in psoriatic skin lesions (Blumberg et al., 2007; Debets
et al., 2001; He et al., 2013; Johnston et al., 2011). Transgenic
mice overexpressing the IL-36 gene in basal keratinocytes
develop psoriatic skin lesions (Blumberg et al., 2007). IL-36R-
deficient mice are protected from imiquimod-induced psoriasi-
form dermatitis (Tortola et al., 2012). Furthermore, accumulating
evidence supports apossible role of IL-36g in drivingTh1 immune
responses. Pseudomonas aeroginosa or TLR3 ligands induce
high levels of IL-36g expression (Chustz et al., 2011; Vos et al.,
2005), and T-bet is required for the induction of IL-36g in myeloid
cells (Bachmann et al., 2012). In addition, IL-36g stimulates Th1
differentiation in vitro, and IL-36R is required for protective im-
mune responses to Aspergillus and Bacillus Calmette-Gue´rin
(BCG) infection (Gresnigt et al., 2013; Vigne et al., 2012). There-
fore, IL-36g is a candidate antitumor cytokine because of its
role in promoting Th1 immune responses. Nevertheless, its func-
tion in other type 1 lymphocytes, such as CD8+ T cells, natural
killer (NK) cells, and gd T cells, which are pivotal antitumor lym-
phocytes, is unknown.
In this study, we sought to examine the role of IL-36g in driving
antitumor immune responses. We determined the direct function
of IL-36g on type 1 lymphocytes, including CD8+ T cells, NK
cells, and gd T cells. We further explored the effect of IL-36gCanon driving antitumor immunity in mice and the role of IL-36g in
human cancer progression.
RESULTS
IL-36R Is Expressed on CD8+ T Cells, NK Cells,
and gd T Cells
To establish the effect of IL-36g on CD8+ T cells, NK cells, and gd
T cells, we first examined the expression of IL-36R in these cells.
We used naive CD4+ T cells as the positive control because it has
been shown that IL-36R is expressed in CD4+ T cells (Vigne et al.,
2012). We then purified naive CD4+ and CD8+ T cells and stimu-
lated these cells in vitro at various time points in the presence of
CD3 and CD28 monoclonal antibodies (mAbs). We collected
cells at 24, 48, and 96 hr and subsequently collected RNA
from these cells. These time points were chosen based on the
fact that they represent distinctive stages of naive-to-effector
T cell differentiation. Similar as in previous studies, IL-36R could
be readily detected in CD4+ T cell RNA. Interestingly, we found
high levels of IL-36R in total RNA from naive and effector CD8+
T cells (Figures S1A and S1B). The level of IL-36R mRNA was
reduced, particularly in CD4+ T cells, upon activation for 48 hr.
In addition, we also found high levels of IL-36R mRNA expres-
sion in NK and gd T cells (Figures S2A and S2B). Therefore,
both adaptive and innate type 1 lymphocytes are potential target
cells of IL-36g.
IL-36g Promoted Early Activation and Expansion
of Naive CD8+ T Cells
Because IL-36R is expressed on naive CD8+ T cells, we sought
to determine whether IL-36g could co-stimulate naive CD8+
T cell activation. Naive CD8+ T cells were isolated from pmel-1
T cell receptor (TCR) transgenic mice (Overwijk et al., 2003).
The cells were subsequently stimulated with anti-CD3 and
anti-CD28 mAbs in the presence of IL-36g, IL-2, and IL-12 alone
or in combination. As expected, the naive T cells were noted to
be enlarged upon activation (Figure 1A). We found that, upon
stimulation for 24 hr, both IL-2 and IL-12 were able to further in-
crease the size of activated T cells in culture (Figure 1A). Interest-
ingly, IL-36g also greatly increased the size of T cells in culture in
a dose-dependent manner and was more effective than IL-2
(Figure 1A, left; Figure S1C). Furthermore, IL-36g, when com-
bined with IL-2 or IL-12, induced additional increases in cell
size (Figure 1A, center and right), thereby indicating that IL-36g
promoted the biomass production during naive T cell activation.
We also measured IL-2 and IFN-g levels at 24 hr and found that
addition of IL-36g significantly enhanced the level of both IL-2
and IFN-g, compared with culture with no cytokine, in a dose-
dependent fashion, thereby revealing the positive role of IL-
36g in promoting naive CD8+ T cell activation (Figure 1B; Fig-
ure S1D). We also noted that IL-2 production in culture with IL-
36gwas higher than in culture with either IL-2 or IL-12 (Figure 1B,
left). The increase in cell size and cytokine production by IL-36g
was partially dependent on IL-2 (Figures S1E–S1G). In addition,
we demonstrated that the effect of IL-36g on cell size and cyto-
kine production was dependent on myd88, a critical signaling
molecule for IL-36R (Figures S1I–S1K). Besides pmel-1 CD8+
T cells, IL-36g also co-stimulated total naive CD8+ T cells puri-
fied directly from C57BL/6 mice (data not shown).cer Cell 28, 296–306, September 14, 2015 ª2015 Elsevier Inc. 297
Figure 1. IL-36g Enhanced Naive CD8+ T
Cell Activation and Expansion and Effector
T Cell IFN-g Production
Naive CD8+ T cells were isolated from pmel-1 TCR
transgenic mice. These cells were subsequently
stimulatedwith2.5mg/mlCD3and1.25mg/mlCD28
plate-bound mAbs in the presence or absence of
human IL-2 (20 U/ml), IL-36g (100 ng/ml), IL12
(10 ng/ml), and IL-36g in combination with either
human IL-2 or IL-12 for various lengths of time.
(A) Cell sizes (forward scatter) were determined by
flow cytometry at 72 hr.
(B) The level of IFN-g and IL-2 at 24 hr was
measured by ELISA.
(C) Proliferation was determined by the CFSE
dilution assay.
(D) The number of live cells was determined by live
cell counting after cells were stained with trypan
blue.
(E) Naive T cells were first stimulated with CD3
mAbs and CD28 mAbs in the presence of various
cytokines (human IL-2, IL-12, and IL-36g as indi-
cated) for 72 hr to generate effector CD8+ T cells.
Effector CD8+ T cells were then washed off the
priming medium, equalized in number, and re-
stimulated with CD3 mAbs for 24 hr. The level of
IFN-g in the supernatant was measured by ELISA.
(F) Effector CD8+ T cells, generated by stimulation with CD3 mAbs, CD28 mAbs, and human IL-2 for 72 hr were washed off the priming medium, equalized in
number, and stimulated with IL-36g, IL-12, or both, as indicated, for 48 hr. The level of IFN-g in the supernatant was measured by ELISA.
Data are shown as mean ± SEM. ***p < 0.001, **p < 0.01, or *p < 0.05 by one-way ANOVA. See also Figure S1.T cells proliferate upon effective activation, which is essential
for adaptive immune responses. Therefore, it is important to
establish whether IL-36g promotes T cell proliferation. Naive
pmel-1 CD8+ T cells were stained with carboxyfluorescein succi-
nimidyl ester (CFSE) and stimulated with CD3 and CD28mAbs in
the presence or absence of IL-36g, IL-2, or IL-12 for 72 hr. The
proliferation of CD8+ T cells was quantified by analyzing the
CFSE dilution by flow cytometry. Compared with T cells cultured
with media alone, those cultured in the presence of IL-36g prolif-
erated at much higher levels (Figure 1C). As a control, both IL-2
and IL-12 also enhanced T cell proliferation. Additionally, IL-36g
increased the number of live cells after 72-hr culture in vitro (Fig-
ure 1D). The enhanced proliferation by IL-36g was partly depen-
dent on IL-2 (Figure S1H). In addition, we showed that the effect
of IL-36g on proliferation was dependent on myd88, a critical
signaling molecule for IL-36R (Figure S1L). These data suggest
that, upon activation, IL-36g promotes clonal expansion of naive
CD8+ T cells.
Upon activation and clonal expansion, CD8+ T cells gain
effector function and produce large quantities of effector cyto-
kines, such as IFN-g, upon re-stimulation. We then determined
whether addition of IL-36g during naive T cell priming affected
the IFN-g production by effector CD8+ T cells. Naive CD8+
T cells were stimulated with plate-bound CD3 and CD28 mAbs
in the presence or absence of IL-36g, IL-2, or IL-12 for 72 hr.
We then washed off the priming media and re-stimulated the
cells with CD3 mAbs for 24 hr. Significant concentrations of
IFN-g were detected in effector T cells generated without added
cytokine in their primary culture. Addition of either IL-2 or IL-12 to
the primary culture further increased IFN-g production upon re-
stimulation (Figure 1E). Addition of IL-36g to the primary culture298 Cancer Cell 28, 296–306, September 14, 2015 ª2015 Elsevier Ingreatly increased the IFN-g production of CD8+ T cells upon sec-
ondary stimulation (Figure 1E). These data suggest that IL-36g
promotes differentiation to effector CD8+ T cells.
IL-36g Synergized with IL-12 to Promote IFN-g
Production by Effector CD8+ T Cells
Members of the IL-1 gene family such as IL-18 and IL-33 have
been shown to synergize with IL-12 in promoting IFN-g produc-
tion in effector CD8+ T cells (Ngoi et al., 2012; Robinson et al.,
1997; Yang et al., 2011). We sought to determine whether IL-
36g has similar properties. Effector CD8+ T cells were cultured
with medium alone, IL-36g, IL-12, or IL-36g and IL-12 together
for 48 hr. The level of IFN-g in the supernatant was determined
by ELISA. Little IFN-g was detected in culture with medium or
IL-36g alone (Figure 1F). Addition of IL-12 to the culture resulted
in production of IFN-g by effector CD8+ T cells, albeit at a very
low level. In contrast, IL-36g and IL-12 together drastically
enhanced IFN-g production (Figure 1F). These data reveal that
IL-36g and IL-12 synergistically promote the function of effector
CD8+ T cells.
IL-36g Effectively Promoted IFN-g Production by gd T
and NK Cells
Other major types of lymphocytes that produce large quantities
of IFN-g include gd T and NK cells. Because we found that IL-
36R was highly expressed in both gd T and NK cells, we sought
to determine whether IL-36g promoted the effector function of
these cells, in particular IFN-g production. We first stimulated
gd T cells with anti-CD3 and anti-CD28 antibodies in the pres-
ence or absence of IL-36g for 72 hr. We found that IL-36g signif-
icantly increased the number of live cells (Figure 2A, right). Wec.
Figure 2. IL-36g Promoted IFN-g Production by gd T and NK Cells
gd T and NK cells were purified from C57BL/6 mice by FACS. gd T cells were
subsequently stimulated with anti-CD3 and anti-CD28 mAbs in the presence
or absence of IL-36g. NK cells were stimulated with medium, human IL-2, IL-
36g, or IL-2 and IL-36g together for 48 hr, and the number of live cells and
levels of IFN-g were measured.
(A and B) The number of live gd T (A) and NK (B) cells was determined by live
cell counting after cells were stained with trypan blue. The level of IFN-g
secreted by gd T (A) and NK (B) cells was measured by ELISA. Data are shown
as mean ± SEM. ***p < 0.001, *p < 0.05 by two-tailed unpaired Student’s t test.
See also Figure S2.also measured the level of IFN-g and found that IL-36g greatly
increased the production of IFN-g in the supernatant (Figure 2A,
left). In addition, NK cells were cultured with IL-2, IL-36g, or IL-2
and IL-36g together for 48 hr, and both the number of live cells
and IFN-g levels were measured. IL-2, as expected, increased
the number of live NK cells in culture (Figure 2B, right). IL-36g
alone, however, did not increase live NK cells in culture. In
contrast, addition of IL-36g and IL-2 together resulted in greater
numbers of live NK cells compared with IL-2 alone (Figure 2B,
right). Our data also showed that NK cells cultured with medium
alone spontaneously produced low amounts of IFN-g. IL-36g
alone did not further enhance the level of IFN-g (Figure 2B,
left). IL-2 increased IFN-g production by cultured NK cells. Strik-
ingly, supernatant from cells cultured with IL-2 combined with
IL-36g had more than 6-fold higher concentrations of IFN-g
compared with those cultured with IL-2 alone (Figure 2B, left).
Together, these data suggest that IL-36g strongly promotes
the effector function of gd T and NK cells, as represented by
IFN-g production.
Tumoral Expression of IL-36g Greatly Inhibited Tumor
Growth and Metastasis
Because of the fact that IL-36g potently enhanced the effector
function of CD8+ T, NK, and gd T cells, combined with previous
studies that showed that IL-36g promoted the function of Th1
cells, we hypothesized that IL-36g could have an antitumor func-Cantion in vivo through its co-stimulatory effects on type 1 lympho-
cytes (Vigne et al., 2011, 2012). To further test this hypothesis
in vivo, we determined whether expression of IL-36g in tumor
cells inhibited tumor progression. First, less immunogenic B16
melanoma cells were used to generate control B16-vector
(B-16-vec) and B16-IL-36g cell clones that expressed mouse
IL-36g. IL-36g was not detected in B16 and B16-vec cells by
qRT-PCR (data not shown). B16 and B16-vec cells grew at
similar rates in C57BL/6 mice. IL-36g expression did not alter
B16 proliferation or survival in vitro (Figure S3A). Control B16-
vec and B16-IL-36g cells were then injected into C57/BL6
mice intradermally (i.d.), and tumor growth was monitored every
2 days. Tumor growth was inhibited significantly upon IL-36g
expression (Figure 3A). In addition, expression of IL-36g in B16
cells greatly improved the survival of tumor-bearing mice (Fig-
ure 3B). Therefore, tumoral expression of IL-36g showed a
powerful antitumor effect in vivo.
In addition to B16 melanoma cells, we also tested the effect of
IL-36g on the progression of transplanted 4T1 breast cancer
cells in BALB/c mice. BALB/c mice are known to generate
strong Th2 but weak Th1 immune responses. Nevertheless,
similar to what we observed in the B16 model, 4T1 cells overex-
pressing IL-36g grew at a much slower rate than 4T1 vector
controls (Figure 3C). Therefore, our data indicated that IL-36g
exerted potent antitumor effects when expressed in tumor cells
transplanted into Th2-prone mice. An important property of 4T1
breast cancer cells is their ability to metastasize, mainly to the
lung, and, therefore, we examined lung metastasis after sacri-
ficing the mice 31 days after tumor cell inoculation. Numerous
tumor nodules were observed in the lungs from 4T1-bearing
mice. In sharp contrast, very few tumor nodules were found in
the lungs of 4T1-IL-36g-bearing mice (Figure 3D). These data
support our hypothesis that IL-36g has pronounced antitumor
functions.
To understand the underlyingmechanisms of the antitumor ef-
fect of tumoral expression of IL-36g, we characterized tumor-
infiltrating leukocytes (TILs) in B16 and B16-IL-36g tumors by
flow cytometry. First, we found that the percentages of CD45+
cells were increased in B16-IL-36g tumors compared with B16
tumors (Figure 4A), suggesting increased inflammatory re-
sponses in B16-IL-36g tumors. We then quantified the various
immune cells within the CD45+ TILs. The frequency of type 1
cells, including CD8+ T, NK, and gd T cells, was examined. The
percentage of tumoral CD8+ T cells was not significantly different
between B16 and B16-IL-36g tumors (Figure 4B). However,
because of a large increase in CD45+ TILs overall, the total num-
ber of CD8+ TILs was increased. This was likely due to increases
in both recruitment and local proliferation of CD8+ T cells (Fig-
ure S4A). Interestingly, the percentage of tumoral NK cells was
increased strikingly in B16-IL-36g versusB16 tumors (Figure 4B).
Similarly, the percentage of gd T cells was much greater in
B16-IL-36g than in B16 tumors (Figure 4C). In sharp contrast
to type 1 lymphocytes, the percentage of B cells, which have
been shown to promote tumor growth (Balkwill et al., 2013),
was reduced greatly in B16-IL-36g compared with B16
tumors (Figure 4C). Further analysis of CD4+ TILs showed an
increase of these cells in B16-IL-36g compared with B16
tumors (Figure 4D; Figure S4B). In addition, higher percentages
of Foxp3+ CD4+ T cells, presumably regulatory T (Treg) cells,cer Cell 28, 296–306, September 14, 2015 ª2015 Elsevier Inc. 299
Figure 3. Tumoral Expression of IL-36g Re-
sulted in Inhibition of Tumor Progression
(A) 1 3 105 B16-vector (B16-vec) or B16-IL-36g
cells were injected intradermally into B6 mice, and
the size of the tumor was monitored every 2 days.
Data (mean ± SEM) are representative of three in-
dependent experiments. Five mice were in each
group. *p < 0.05, determined byMann-Whitney test.
B16-vec and B16-IL-36g were compared.
(B) The survival of mice was monitored. Six mice
were in each group. The p value was based on a log
rank test.
(C) 1 3 105 4T1-vector or 4T1-IL-36g cells were in-
jected into the mammary fat pads of BALB/c mice,
and thesizeof the tumorwasmonitoredevery2days.
Data (mean ± SEM) are representative of three in-
dependent experiments. Five mice were in each
group. *p < 0.05, determined by Mann-Whitney test.
(D) Metastatic tumor nodules in the lung were
quantified 30 days after 4T1 and 4T1-IL-36g tumor
inoculation.
Data (mean ± SEM) are representative of three in-
dependent experiments. Five mice were in each
group. **p < 0.01, determined by two-tailed un-
paired Student’s t test. See also Figure S3.were present in B16-IL-36g than in B16 tumors (Figure 4D, right;
Figure S4B). These data suggest that strong type 1 immune
responses were generated in B16-IL-36g tumors and that such
immune responses were regulated by elevated numbers of
Treg cells.
The tumor immunosuppressive microenvironment is domi-
nated by myeloid-derived suppressor cells (MDSCs) (Gabrilo-
vich and Nagaraj, 2009). In mice, these cells express high
and intermediate levels of Gr1 and are positive for CD11b. As
expected, we observed high levels of Gr1high neutrophilic
MDSCs (NMDSCs) and Gr1 intermediate (Gr1int) monocytic
MDSCs (MMDSCs) in B16 tumors. Consistent with their
immunosuppressive role, these cells expressed lower levels
of major histocompatibility (MHC) class II molecules (Figure 4E,
left). In contrast, the percentage of Gr1high CD11b+ NMDSCs
was reduced drastically in the B16-IL-36g tumor (Fig-
ure 4E). We also found that the level of MHC class II mole-
cules was much higher in Gr1high and Gr1int cells in the
B16-IL-36g tumor compared with that in the B16 tumor (Fig-
ure 4E, right). Similar changes of MHC class II were observed
in MDSCs in spleens (Figure S4C). This was likely due to
IFN-g produced by Th1, CD8+ T, NK, and gd T cells. Therefore,
our data indicated that IL-36g promoted type 1 immune re-
sponses in the tumor microenvironment, decreased the per-
centage of NMDSCs, and increased MHC class II expression
on all MDSC subsets, thereby promoting antitumor immune
responses.
To further understand the nature of tumoral inflammation in
B16-IL-36g and B16 tumors, we characterized the expression
profile of cytokines in resected tumors. Consistent with a strong
type 1 immune response, both IL-12 and IFN-g were greatly
induced in B16-IL-36g compared with B16 tumors (more than
200- and 40-fold, respectively) (Figure S4D). In addition, tumor
necrosis factor a (TNF-a) and granzyme B were also highly upre-
gulated in B16-IL-36g compared with B16 tumors (Figure S4D).
Interestingly, proinflammatory cytokines such as IL-17a, IL-23,300 Cancer Cell 28, 296–306, September 14, 2015 ª2015 Elsevier Inand IL-1b were also increased in the B16-IL-36g tumor versus
the B16 tumor, although the level of increase was less than
that of IL-12 or IFN-g (Figure S4D). IL-10, which was likely
secreted by tumoral Treg cells, was also higher in B16-IL-36g tu-
mors than in B16 tumors, suggesting that a self-limiting mecha-
nism was induced in B16-IL-36g tumors. These observations
indicate that IL-36g induced effective antitumor immune re-
sponses associated with the elevation of a diverse array of
cytokines.
Tumoral Expression of IL-36g Induced Adaptive Tumor
Antigen-Specific CD8 T Cell Responses
Our findings that tumor cell expression of IL-36g elicited greatly
increased tumor-infiltrating CD8+ T and NK cells prompted us to
explore whether systemic tumor antigen-specific T cells could
be induced at a higher level upon tumoral expression of IL-
36g. To address this question, we isolated CD8+ T cells from
the spleens of 4T1 or 4T1-IL-36g tumor-bearing mice. We
then co-cultured CD8+ T cells with irradiated tumor cells in the
presence of antigen-presenting cells (APCs) isolated from the
spleens of naive BALB/c mice for 4 days. Levels of IFN-g in
these cultures were measured by ELISA. We found that an
average of 7 ng/ml IFN-g was produced by CD8+ T cells from
4T1-bearing mice (Figure S4E). In contrast, an average of
36 ng/ml IFN-g was produced by CD8+ T cells isolated from
4T1-IL-36g-bearing mice (Figure S4E). These data demon-
strated that tumoral expression of IL-36g led to a significant
increase of tumor antigen-specific CD8+ T cells, thereby sup-
porting the role of IL-36g in eliciting a tumor-specific adaptive
immune response.
The Antitumor Effect of IL-36gWas Dependent on Host
Expression of IL-36R
To further determine whether host cell IL-36R signaling is critical
for mediating the antitumor effect of IL-36g, we injected B16 and
B16-IL-36g into wild-type (WT) and IL-36R/ mice andc.
Figure 4. Tumoral Expression of IL-36g
Shaped the Immunogenic Tumor Microenvi-
ronment
(A–E) 1 3 105 B16-vec or B16-IL-36g cells were
injected i.d. into B6 mice. On day 24, tumors were
resected and processed to generate a single-cell
suspension.
(A) Percentages of CD45+ cells in the tumor cell
suspension.
(B) Representative flow cytometric plots and per-
centages of CD8+ T or NK1.1+ cells within the
gated CD45+ population in tumors.
(C) Representative flow cytometric plots and per-
centages of gd T or B cells within the CD45+ pop-
ulation in the tumor microenvironment.
(D) Percentages of the CD4+ T cells within the
CD45+ TILs and percentages of CD4+Foxp3+
population within the CD4+ TILs.
(E) Representative flow cytometric analysis of
CD11b+ sub-populations and percentages of
CD11b+ sub-populations of CD45+ immune cells
and percentages of MHC class II expression on
three CD11b+ sub-populations.
Data (mean ± SEM) are averages of four indepen-
dent experiments. *p < 0.05, **p < 0.01, deter-
mined by two-tailed unpaired Student’s t test. See
also Figure S4.monitored tumor growth and tumoral immune responses. We
found that IL-36g expression in B16 cells failed to inhibit tumor
growth or prolonged survival of IL-36R/ mice (Figures 5A
andB). Interestingly, the B16 tumor grew at a slightly accelerated
rate in IL-36R/mice compared with WT mice (Figure 5B), sug-
gesting that IL-36 signaling is involved in spontaneous antitumor
immune responses in this model. Further analysis of tumor-infil-
trating lymphocytes revealed that no difference was found in the
percentages of CD45+ cells, NK cells, gd T cells, IFN-g+ CD4+
cells, and IFN-g+ CD8+ TILs in B16 and B16- IL-36g tumors iso-
lated from IL-36R/ mice (Figures 5C–5G; Figures S5A–S5D).
These data suggest that the antitumor effect of IL-36g is depen-
dent on IL-36R in host cells.
CD8+ T Cells and NK Cells Mediated the Antitumor
Effect of IL-36g
Because CD8+ T cells and NK cells were increased in tumors
overexpressing IL-36g and tumor-specific CD8+ T cells were
increased in IL-36g-tumor-bearing mice, we sought to deter-
mine whether CD8+ T cells or NK cells are required for the
antitumor effect of IL-36g. We used anti-CD8 and NK anti-
bodies to deplete CD8+ T cells and NK cells, respectively,
and then examined tumor progression in these mice
compared with mice injected with control antibodies. B16-IL-
36g tumors grew at much reduced rates compared with the
B16-vec control tumor (Figure 6A). Injection of either anti-NK
or anti-CD8 mAbs partially reversed the inhibition by IL-36g
(Figure 6A). Therefore, both NK and CD8+ T cells contributed
to the antitumor function of IL-36g. To further establish the
role of lymphocytes in mediating the antitumor effect, we uti-
lized Rag2/IL2Rg double-deficient mice, which lack T cells,
NK cells, gd T cells, and B cells. Strikingly, IL-36g completely
failed to inhibit tumor growth in Rag2/IL2Rg double-deficientCanmice (Figure 6B). These data further established the critical
role the immune system plays in mediating the antitumor func-
tion of IL-36g.
The Requirement of IFN-g and Cytolytic Machineries
for the Antitumor Function of IL-36g
To further investigate the effector molecules required for the anti-
tumor function of IL-36g, we examined tumor growth in IFN-g/
and perforin/ mice. The B16-IL-36g tumor grew significantly
faster in IFN-g/ mice compared with WT mice (Figure 6C). In
contrast, B16-IL-36g grew slightly faster in perforin/ mice
compared with WT mice (Figure 6C). These data suggest that
IL-36g exerts its antitumor function mainly through IFN-g.
IL-36g Enhanced Tumor Cell-Based Vaccination
Because tumoral expression of IL-36g increased the immunoge-
nicity of tumor cells, we sought to determine whether IL-36g
could be used to boost the efficacy of tumor vaccination.
C57BL/6 mice were first inoculated with B16 cells i.d. For tumor
vaccination, B16 and B16-IL-36g cells were irradiated and then
injected subcutaneously (s.c.) in tumor-bearing mice starting
on day 5 after tumor inoculation. The injection was repeated
every 4 days and a total of five times (Figure 7A). Tumor growth
and survival were monitored every 2 days. Injection of irradiated
B16 cells did not show any inhibitory effect on tumor growth or
survival of tumor-bearing mice compared with PBS-injected
control mice (Figures 7B and 7C). In contrast, tumor growth
was inhibited significantly in mice injected with irradiated B16-
IL-36g cells (Figure 7B). In addition, the survival of B16-IL-36g-
vaccinated mice was prolonged compared with either PBS- or
B16-injected mice (Figure 7C). Therefore, our data indicate that
tumoral expression of IL-36g can serve as an effective tumor
vaccination approach.cer Cell 28, 296–306, September 14, 2015 ª2015 Elsevier Inc. 301
Figure 5. The Antitumor Effect of IL-36g Is Dependent on IL-36R in the Host Mice
(A) 13 105 B16-vec or B16-IL-36g cells were injected intradermally into WT and IL-36R/ mice, and the survival of mice was monitored. Six mice were in each
group. The p value was based on a log rank test.
(B) 13 105 B16-vec or B16-IL-36g cells were injected intradermally intoWT and IL-36R/mice, and the size of the tumorwasmonitored every 2 days. Four to five
mice were in each group. #p < 0.05, *p < 0.05, ***p < 0.001, determined byMann-Whitney test. For * and ***, B16-vec and B16-IL-36gmice were comparedwith to
WT mice. For #, B16-vec mice were compared with the WT and IL-36R/ groups. The tumors were resected on day 17 and subjected to the following analysis.
(C) Percentages of CD45+ TILs in the tumor microenvironment.
(D) Percentages of NK cells within CD45+ TILs.
(E) Percentages of gd T cells within CD45+ TILs.
(F) Percentages of IFN-g+ T cells within CD4+CD45+ TILs.
(G) Percentages of IFN-g+ T cells within CD8+CD45+ TILs.
Data (mean ± SEM) are averages of four independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 by two-tailed unpaired Student’s t test. Four to five mice
were in each group. See also Figure S5.IL-36g Enhanced IFN-g Production by Human CD8+ T
Cells, and Levels of IL-36g Expression Correlated
Inversely with Melanoma and Lung Cancer Progression
A strong effect of IL-36g on murine CD8+ T cells prompted us to
further investigate whether IL-36g had a similar function in hu-
man CD8+ T cells. To this end, we stimulated human CD8+
T cells in the presence or absence of IL-36g and found that IL-
36g greatly increased IFN-g production (Figure 8A). Therefore,
human IL-36g also enhances IFN-g production in CD8+ T cells.
To establish the relevance of IL-36g in human cancer, we
searched NCBI GEO as well as the Oncomine database to iden-
tify human tumors expressing IL-36g. Our analysis of the GEO
datasets revealed that human IL-36g expression was lower in
metastatic melanoma than in primary melanoma (Figure 8B).
Additionally, IL-36g is expressed at a lower level in melanoma
compared with melanoma precursors (Figure S6). Besides mel-
anoma, we found that IL-36g is also expressed in several other
cancer types, such as lung cancer, especially squamous cell car-
cinoma, head and neck cancer, esophageal cancer, and colo-
rectal cancer (data available at the Oncomine database).302 Cancer Cell 28, 296–306, September 14, 2015 ª2015 Elsevier InTo further substantiate our hypothesis, we used human cancer
samples from human lung cancer patients. Our quantitative qRT-
PCR analysis showed that IL-36g was expressed in lung cancer
tissues and that its expression was reduced in later-stage cancer
tissues compared with earlier-stage cancer tissues (stage III
versusstages I and II) (Figure8C).Collectively, thesedata suggest
that IL-36g has potential antitumor functions in human cancer.
DISCUSSION
This study has shown that IL-36g directly promotes effector dif-
ferentiation of type 1 lymphocytes in vitro and exerts strong anti-
tumor immune responses in vivo. First we established that
IL-36R was expressed in murine CD8+, NK, and gd T cells and
that IL-36g directly promoted IFN-g production and proliferation
of these cells in vitro. Second, we showed that tumoral expres-
sion of IL-36g increased the number of TILs including CD8+,
NK, and gd T cells, in vivo and exerted a strong antitumor effect.
Third, we found that the adaptive tumor antigen-specific CD8+
T cell immune responses were enhanced greatly by IL-36g.c.
Figure 6. Both NK andCD8+ T Cells Contrib-
uted to the Antitumor Effect of IL-36g
(A) 1 3 105 B16-vector or B16-IL36g cells were
injected i.d. into C57BL/6 mice (n = 5). These mice
were injected intraperitoneally with anti-CD8 or
anti-asialo GM1 antibodies or control IgG three
times after tumor inoculation (days 1, 7, and 14).
Tumor sizes were measured every 2 days. *p <
0.05 by one-way ANOVA, comparing the NK and
CD8-depletion B16-IL36g groups to the B16-
IL36g IgG group.
(B) 1 3 105 B16-vector or B16-IL36g cells were
injected i.d. into C57BL/6 or Rag2/IL2Rg double-
deficient mice (double knockout [DKO]) (n = 5).
Tumor sizes were measured every 2 days. *p <
0.05, **p < 0.01 by one-way ANOVA, comparing
the group of WT mice inoculated with B16-IL36g
cells with the group of WT mice inoculated with
B16-vec cells.
(C) 1 3 105 B16-vector or B16-IL36g cells were
injected i.d. into C57BL/6, IFN-g/, or Prf1/
mice (n = 5). Tumor sizes were measured every
2 days. *p < 0.05, **p < 0.01 by one-way ANOVA,
comparing WT to IFN-g/ or Prf1/ mice, which
were inoculated with B16-IL36g cells.Fourth, we showed that the antitumor effect of IL-36g was
dependent on intact IL-36R and that IL-36 signalingwas involved
in spontaneous antitumor immune responses. Fifth, tumor cells
expressing IL-36g functioned as an effective tumor vaccine.
Last, we demonstrated that human IL-36g promoted IFN-g pro-
duction by humanCD8+ T cells and that its expression correlated
inversely with melanoma and lung cancer progression. Based on
these findings, our study establishes a role of IL-36g that has
important implications for tumor immune therapy.
IL-36 has been established as a pivotal mediator of skin
inflammation. IL-36R signaling is essential for control of the path-
ogenic IL-23/IL-17/IL-22 axis and development of psoriasiform
dermatitis in response to environmental cues such as imiquimod
(Tortola et al., 2012). Recent data suggest that IL-36 can also
promote CD4+ T cell-mediated type 1 immune responses and
that IL-36R signaling is involved in Th1 immune responses
against Mycobacterium bovis BCG in vivo (Vigne et al., 2012).
However, the role of this cytokine in CD8+ T cell-mediated im-
mune responses has not been explored. CD8+ T cells play a crit-
ical role in tumor immunity and anti-viral immune responses. Our
analysis revealed that the expression level of IL-36g is reduced in
more advanced human melanoma and lung cancer, indicating a
potential role of this cytokine in tumor progression. Our mouse
experiments illustrate a profound effect of IL-36g on the differen-
tiation and function of CD8+ T cells. Furthermore, we demon-
strated that IL-36g promoted antitumor immune responses
in vivo and that CD8+ T cells and NK cells were required for the
antitumor effect of IL-36g. IL-36R is also expressed in DCs and
monocytes (Foster et al., 2014; Tortola et al., 2012). It is also
possible that some of the antitumor effects are mediated by
myeloid cells. Nonetheless, our study established an unappreci-
ated biological function of IL-36g in promoting CD8+ T cell-medi-
ated immune responses and demonstrated that such a property
can be harnessed to promote antitumor immunity. In addition,Canour finding also suggests that IL-36g might be involved in other
CD8+ T cell-mediated adaptive immune responses, such as
those seen during viral infection.
Current immunotherapy based on the blockade of checkpoint
molecules relies on the amplification of spontaneous antitumor
immune responses (Brahmer et al., 2012; Fourcade et al.,
2010; Gao et al., 2012; Sakuishi et al., 2010; Topalian et al.,
2012; Wolchok et al., 2013). Such an approach is limited by
the requirement for existing tumor-specific immune responses
(Ascierto et al., 2013). Therefore, inducing an appropriate inflam-
mation in a tumor should greatly increase tumor immunogenicity
and, thereby, help break immune tolerance to tumor antigens
and increase response rates to immunotherapy. Our study
strongly suggests that IL-36g can serve as a cytokine that en-
hances tumor-specific immune responses and breaks tolerance
against tumor antigens. Two possible immunotherapeutic ap-
proaches can be explored further to take advantage of this unap-
preciated knowledge of IL-36 biology. One approach will reply
on the specific delivery of IL-36g to the tumor site. This can be
achieved through either oncolytic viruses or antibody-cytokine
fusion techniques (Guo et al., 2014; Kontermann, 2012). Alterna-
tively, IL-36g can be used to boost tumor vaccination in a
cell-based vaccine approach, as demonstrated in this study.
Therefore, our study laid the foundation for further exploring IL-
36g in cancer immunotherapy.
EXPERIMENTAL PROCEDURES
Animals
C57BL/6j (B6; H2Kb), BALB/c (H2Kd), IFN-g/, Prf1/, and Rag2IL2Rg dou-
ble-deficient mice were purchased from The Jackson Laboratory. MyD88KO
mice on a C57BL/6 background were a generous gift from R. Medzhitov (Ho-
ward Hughes Medical Institute, Yale University). IL-36R/ mice (C57BL/6-
Il1rl2 < tm1Hblu > (Derer et al., 2014)) were provided by Amgen via Taconic
under an approved material transfer agreement. All mice were housed in thecer Cell 28, 296–306, September 14, 2015 ª2015 Elsevier Inc. 303
Figure 7. Tumoral Expression of IL-36g
Boosted the Efficacy of Tumor Vaccination
(A) C57BL/6 mice were challenged with 1 3 105
B16 cells i.d.
(B and C) PBS-treated and irradiated 5 3 105 B16
and B16-IL-36g cells were injected s.c. on days 5,
9, 13, 17, and 21 after B16 inoculation. Mice were
monitored for tumor growth and survival every
other day. Data are representative of three inde-
pendent experiments. Results are shown as
mean ± SEM. *p < 0.05, **p < 0.01. Two-tailed
unpaired Student’s t test was used for the analysis
of tumor growth, and a log rank test was used for
the analysis of survival.specific pathogen-free facility of the University of Pittsburgh School of Medi-
cine or Soochow University. Experiments were conducted under an institu-
tional animal care and use committee-approved protocol and in accordance
with NIH guidelines.
Selection of Human Cancer Tissue Samples
Lung cancer tissue (squamous cell carcinoma) specimens were obtained from
pathologically confirmed and newly diagnosed non-small-cell lung cancer
(NSCLC) patients who received operations in the Cardiothoracic Surgery
Department of the First Affiliated Hospital, Soochow University. This study
was approved by the ethics committee of the First Affiliated Hospital of Soo-
chow University. Informed consent was obtained from all patients.
Plasmid Construction
The pcDEF3-Dap10 vector was obtained from Dr. Lawrence Kane (University
of Pittsburgh). Themature peptide (G13–S164) sequence of murine IL-36gwas
synthesized by Genewiz. The IL-36g expression construct was generated by
fusing the nucleotide sequence encoding the human CD8a signal sequence
to the 50 end of IL-36g (G13–S164) sequence, which was then ligated into
the pcDEF3-Dap10 vector via BamH1 and EcoR1. The construct was
confirmed to be correct by DNA sequencing analysis (available upon request).
Tumor Cell Culture and Generation and Characterization of IL-36g-
Expressing Cell Lines
4T1 cells were cultured inDMEMplus 10% fetal calf serum (FCS), andB16 cells
were cultured inRPMI 1640mediumplus10%FCS. The IL-36gexpression vec-
tor was transfected into B16 cells and 4T1 cells using Lipofectamine 2000 (In-
vitrogen/Life Technologies) according to the manufacturer’s instructions. An
empty vector (pcDEF3) was transfected into B16 cells and 4T1 cells as a con-
trol. 24 hr post-transfection, cells were diluted into culture plates and selected
withG418 (Sigma) at a concentrationof 600mg/l. Stable cell lineswere selected
by further subcloning. Expression levels of IL-36g were determined by qRT-
PCR. Protein expression was examined by western blot using rabbit anti-IL-
36g antibodies from two sources (anti-IL1F9 antibody, amino acids 5–149,
catalog no. LS-C294790, LifeSpan Biosciences, and one generated by
T.L.D.’s lab) (Figure S3B). The proliferation of IL-36g-expressing cell lines
was comparable with that of control vector-transfected cell lines (Figure S3A).
Primary Lymphocyte Culture and Stimulation
To determine IL-36R expression, single-cell suspensions were made from
spleens and lymph nodes of C57BL/6 mice. Naive CD4+, CD8+ T (CD62L+
CD44), NK (DX5+), and gdT cells were purified by fluorescence-activated
cell sorting (FACS) or magnetic bead-based methods (Miltenyi Biotec). The
naive CD4+ and CD8+ T cells were stimulated with 5 mg/ml plate-bound anti-
CD3 mAbs (clone 145-2C11) and 2.5 mg/ml plate-bound anti-CD28 mAbs304 Cancer Cell 28, 296–306, September 14, 2015 ª2015 Elsevier Inc.(clone 37.51) in complete RPMI medium (cRPMI,
RPMI 1640 medium supplemented with 10%
heat-inactivated FCS, 2 mM L-glutamine, 50 mM
2-mercaptoethanol (2-ME), 100 U/ml penicillin,
and 100 mg/ml streptomycin) under the Th1 condi-tion, which included human IL-2 (20 U/ml, obtained from the BRB Preclinical
Repository), IL-12 (3.4 ng/ml), and anti–IL-4 mAbs (10 mg/ml, clone 11B11,
BRB Preclinical Repository). After 96 hr, cells were harvested, washed, and
re-stimulated with 1 mg/ml plate-bound anti-CD3 in cRPMI medium for 3 hr.
NK cells were stimulated with 20 U/ml huIL-2 for 72 hr, and gdT cells were stim-
ulated with 5 mg/ml plate-bound anti-CD3 antibody for 72 hr in cRPMImedium.
Recombinant mouse IL-36g (G13–S164, catalog no. 6996-IL-010/CF, R&D
Systems) or recombinant human IL-36g/IL-1F9 (S18–D169, catalog no.
6835-IL-010/CF, R&D Systems) was used to stimulate mouse or human
T cells, respectively.
Tumor Model
B16 cells were injected intradermally into B6 mice, and the size of tumor was
monitored every 2 days. 4T1 cells were injected into the mammary fat pads of
BALB/c mice and the size of the tumor was monitored every 2 days. To study
the contribution of NK and CD8+ T cells to the antitumor effect of IL-36g, each
B6 mouse was injected with 200 mg anti-CD8 (clone 53-6.72, BioXcell), 15 ml
anti-asialo GM1 (Wako Pure Chemicals Industries) antibodies or control immu-
noglobulin G (IgG) three times after tumor inoculation (days 1, 7, and 14).
Metastatic 4T1 tumor nodules were enumerated after the India ink staining
procedure, as reported previously (Lewis et al., 2005). Briefly, India ink solution
was injected through the trachea to inflate the lungs, and the lungs were
stained for 5min. The lungswere then removed and placed in Fekete’s solution
(70% alcohol, 10% formalin, and 5% acetic acid) for destaining. Tumor nod-
ules did not absorb India ink, which resulted in the normal lung tissue staining
black and the tumor nodules remaining white. Tumor nodules were counted
blindly by two independent investigators.
Tumor Vaccination
C57BL/6 mice were inoculated with 13 105 B16 cells i.d. 53 105 B16 or B16-
IL-36g cells that had been irradiated at 120 Gy were injected s.c. on days 5, 9,
13, 17, and 21 after B16 inoculation. Mice were monitored for tumor growth
and survival every other day.
Analysis of Tumor-Infiltrating Lymphocytes and Myeloid-Derived
Suppressor Cells
Tumors were dissected and transferred into RPMI medium. Tumors were dis-
rupted mechanically using scissors, digested with a mixture of 0.3 mg/ml
DNase I (Sigma-Aldrich) and 0.25 mg/ml Liberase TL (Roche) in serum-free
RPMI medium for 25 min, and dispersed through a 40-mm cell strainer (BD
Biosciences). TILs were further purified with a gradient according to the man-
ufacturer’s protocol, washed, and re-suspended in Hank’s balanced salt solu-
tion (HBSS) with 1% FCS for analysis. The various cell populations were
analyzed by flow cytometry. Flow cytometric analysis was performed using
a FACS flow cytometer (BD Biosciences).
Figure 8. Human IL-36g Promotes CD8+ T Cell Function, and Its
Expression Is Reduced in Advanced Melanoma and Lung Cancer
(A) Human CD8+ T cells were purified from PBMCs from health donors using
CD8magnetic beads. These cells were subsequently stimulated with anti-CD3
antibody in the presence or absence of IL-36g for 96 hr. The supernatants were
assayed for IFN-g by ELISA. **p < 0.01 by Student’s t test.
(B) Expression of human IL-36g in primary and metastatic melanoma. The
expression profile was found by searching the NCBI GEO database. Data are
from profile GDS3966/220322_at /IL-36g. Data were downloaded, reanalyzed,
and presented as mean relative expression level ± SEM. **p < 0.01 by
Student’s t test.
(C) Quantitative RNA analysis of human IL-36g in the early and late stages of
lung squamous cell carcinoma.DCT =CTIL-36gCTGAPDH. Results are mean ±
SEM. The p value was obtained by Student’s t test.
See also Figure S6.Evaluation of Tumor Antigen-Specific CD8+ T Cell Immune
Responses
CD8+ T cells were isolated from the spleens of 4T1-vector (4T1-vec) or 4T1-IL-
36g tumor-bearing BALB/c mice by positive selection using immunomagnetic
beads according to the manufacturer’s protocol (CD8a [Ly-2] MicroBeads,
Miltenyi). APCs were prepared from splenocytes from naive BALB/c mice by
CD4+ and CD8+ T cell depletion and subsequent irradiation at 30 Gy. Purified
CD8+ T cells (23 106/well) were then co-cultured with 60 Gy-irradiated 4T1 tu-
mor cells (53 105/well) and irradiated APCs (53 104/well) in the presence of 20
IU/ml recombinant huIL-2 (BRB Preclinical Repository) in 96-well round-bot-
tom plates in a humidified incubator at 37C and 5% CO2. After 96 hr, cell-
free supernatants were harvested and assayed for IFN-g using a murine
IFN-g ELISA kit (BD Biosciences/BD Pharmingen).
Examination of IL-36g Function on Human CD8+ T Cells
Human peripheral blood mononuclear cells (PBMCs) were isolated from
healthy peripheral blood by Ficoll-Paque Plus (Sigma-Aldrich) density gradient
centrifugation. CD8+ T cells were then purified by positive selection using im-
munomagnetic beads according to the manufacturer’s protocol (anti-CD8a
[OKT8], MicroBeads, Miltenyi) and passed through amagnetic cell-sorting col-
umn (Miltenyi). CD8+ T cells were stimulated with plate-bound anti-humanCD3
(OKT3) antibodies for 96 hr in the presence or absence of human IL-36g proteinCan(S18–D169, catalog no. 6835-IL-010/CF, R&D Systems), and the level of IFN-g
in the supernatant was measured using a human IFN-g ELISA kit (BioLegend).
Statistical Analysis
A two-tailed unpaired Student’s t test, Mann-Whitney test, or one-way ANOVA
was performed as indicated. p < 0.05 was considered significant.
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